| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -17,369 | -10,146 |
| Purchase of fixed assets | 0 | 0 |
| Net cash used in investing activities | 0 | 0 |
| Proceeds from exercise of warrants | 1,121 | 10 |
| Payment of tax liability for vested restricted stock units | 0 | 0 |
| Proceeds from sale of common stock, pre-funded and common warrants and warrant inducement, net of issuance and transaction costs | 18,676 | 13,412 |
| Net cash provided by financing activities | 19,797 | 13,422 |
| Effect of exchange rate changes on cash and cash equivalents | -3 | 3 |
| Net increase (decrease) in cash and cash equivalents | 2,425 | 3,279 |
| Cash and cash equivalents at beginning of period | 4,278 | - |
| Cash and cash equivalents at end of period | 6,703 | - |
Moleculin Biotech, Inc. (MBRX)
Moleculin Biotech, Inc. (MBRX)